What Is TB-500? Thymosin Beta-4 Naming

TB-500 and thymosin beta-4 should not automatically be read as identical structural names. A primary analytical study assigned Ac-LKKTETQ, an acetylated seven-residue fragment, to the TB-500 material it examined. Separate sequence studies describe full-length thymosin beta-4 as 43 residues. For a UK research purchase, the relevant question is the exact material specified by the listing and lot report (fragment study; human sequence study).

Why begin with the structural designation?

The 2012 analytical paper identifies the N-terminal acetylated 17–23 fragment of human thymosin beta-4 and writes its sequence as Ac-LKKTETQ. The authors’ assignment includes both the fragment and the modification. A summary that keeps only the parent name loses part of the chemical description (Esposito and colleagues).

Before comparing papers or catalogue entries, write down the complete designation. Keep the listing name, parent sequence, fragment boundaries and terminal modification in separate columns if necessary. A similar label is not a reason to fill in an absent structure, and an abbreviation should not replace the information needed to identify the material.

What does the older full-length research describe?

Low and colleagues reported the sequence of thymosin beta-4 isolated from calf thymus in 1981. They described a polypeptide containing 43 amino acid residues with an acetyl group at the amino terminus. This is a structural account of the material studied, not a certificate for a current supplier’s catalogue (original publication).

The species and source material belong in the citation summary. Leaving them out can make a reference appear to establish more than it does. Preserve the distinction between the historical sequence evidence and the separate question of what a present-day vial contains.

Is there a human sequence reference?

A 1987 paper described a human cDNA clone derived from a peripheral-blood-leukocyte library. The clone contained the coding sequence for a 43-residue thymosin beta-4 peptide, and the paper also examined messenger RNA expression in cell populations and cell lines. The library was prepared using material from a patient (Gondo and colleagues).

Human-source material does not make this a clinical trial. Its sequence and expression measurements answer molecular questions. Do not convert the library donor into a trial population or present the work as a test of a research product that the paper did not examine.

How should the TB-500 finding be stated?

State that the 2012 researchers identified Ac-LKKTETQ in the material examined using chromatography and high-resolution mass spectrometry. The abstract does not state how many commercial products or lots were included. That wording preserves the analytical observation without turning it into a claim about every present-day item with the same label (primary record).

Do not silently extend the sample scope. A paper about a particular material is not a market-wide identity survey unless its methods actually establish that scope. Similarly, a current catalogue description cannot retroactively redefine the structure identified in an earlier publication.

What the evidence actually shows

Bovine sequence work, 1981: the source was calf thymus, and the structural endpoint was the amino acid sequence of thymosin beta-4, described as 43 residues with an acetylated amino terminus. A total specimen count and overall duration are not given in the accessible abstract. These are not supplied by inference (primary publication).

Human molecular work, 1987: a leukocyte-derived cDNA library provided the clone used for sequence analysis, with additional expression measurements in cell populations. The endpoints included the coding sequence and messenger RNA levels. The abstract does not give an overall sample total or complete duration; the library donor is not substituted for the full experimental count (primary abstract).

Material identification, 2012: the examined TB-500 material was assigned the acetylated 17–23 fragment, Ac-LKKTETQ. The relevant endpoint was chemical identity. The abstract does not report lot numbers, a total commercial-sample count or an overall study duration. It should therefore not be described as a survey of all suppliers (analytical study).

Does a different name mean a failed identity test?

The cited publications concern their own experimental materials, not a particular ETHOS lot. They establish full-length sequence descriptions and a separate fragment assignment, but do not provide a batch verdict for this store (1981 sequence work; 1987 human work; 2012 fragment work).

Regard a difference between a label and report as an unresolved question. Ask what the specification required, which material was tested and what evidence the laboratory used for its assignment. Avoid both shortcuts: assuming the names are interchangeable and calling the batch a failure before those questions are answered.

How should a UK catalogue entry be reviewed?

Compare the exact listing designation with the vial label and its matching analytical record. Look for the sequence or another unambiguous structural specification, terminal modifications and the report’s identity evidence. If the documents repeat only an informal name, request the missing information rather than filling it from an unrelated product page.

The ETHOS UK tissue-biology research category provides catalogue navigation, not proof that all materials in it share a structure. This guide does not assign a full-length or fragment identity to an unresolved ETHOS TB500 listing. It also does not determine regulatory classification or change the laboratory-only intended-use boundary.

How this relates to research materials

ETHOS’s “8X tested” statement means eight distinct tests before shipment, with batch COAs available through the public portal. The UK quality-documentation page provides store context. Match the lot and material name before comparing analytical values.

The UK COA guide explains report fields, while the HPLC and mass spectrometry guide separates identity, chromatographic purity and content questions. Keep the label, report and documented storage requirements together. For a later storage interval, seek evidence addressing that interval rather than assuming a one-time result covers every future condition.

Frequently asked questions

Which fragment did the analytical paper identify?

The 2012 paper identified Ac-LKKTETQ, the N-terminal acetylated 17–23 fragment.

How does that differ from the full-length sequence?

The cited full-length sequence studies describe 43 residues, not the seven-residue fragment (1981; 1987).

Does the guide verify an ETHOS TB500 product?

No. It explains published structural descriptions and leaves any unresolved listing identity for confirmation against its own documentation.

What should I request if documents disagree?

Request a lot-matched explanation of the intended structure and analytical assignment. Do not infer equivalence from a shortened name alone.

Research use only. ETHOS supplies laboratory research materials, not products for human or veterinary use. This guide concerns identity and documentation, not product outcomes or personal-use advice.